AZNAcerta Pharma BVRunning, no new patients
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 24 (final count)
- Started
- Jan 25, 2016
- Main results expected
- Jun 26, 2020
- Fully finished
- Apr 1, 2026
- Results posted
- Jul 29, 2020
What counts as success
The trial's main goal(s), called the “primary outcome.”
Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.
Measured over: On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02586857 · record last updated 2026-03-25 · checked 2026-11-09 15:47 UTC